Vident Advisory LLC Increases Stock Position in Novo Nordisk A/S $NVO

Key Points

• Vident Advisory LLC increased its stake in Novo Nordisk A/S by 23.4%, now owning 51,146 shares valued at $3,552,000.
• Several analysts have downgraded Novo Nordisk A/S, with HSBC and UBS reducing their ratings to "hold" and "neutral," respectively, amidst a current consensus rating of "Hold."
• Novo Nordisk A/S reported earnings of $0.97 per share for the last quarter, beating the consensus estimate of $0.93, and announced a semi-annual dividend of $0.4119 per share.

Vident Advisory LLC raised its stake in Novo Nordisk A/S (NYSE:NVO - Free Report) by 23.4% during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 51,146 shares of the company's stock after acquiring an additional 9,685 shares during the period. Vident Advisory LLC's holdings in Novo Nordisk A/S were worth $3,552,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Copeland Capital Management LLC increased its holdings in Novo Nordisk A/S by 184.8% in the 1st quarter. Copeland Capital Management LLC now owns 393 shares of the company's stock valued at $27,000 after acquiring an additional 255 shares during the last quarter. North Capital Inc. bought a new stake in shares of Novo Nordisk A/S in the 1st quarter worth about $27,000. Park Square Financial Group LLC bought a new stake in shares of Novo Nordisk A/S in the 4th quarter worth about $29,000. Stone House Investment Management LLC bought a new stake in shares of Novo Nordisk A/S in the 1st quarter worth about $30,000. Finally, Disciplina Capital Management LLC increased its holdings in shares of Novo Nordisk A/S by 162.3% in the 1st quarter. Disciplina Capital Management LLC now owns 480 shares of the company's stock worth $33,000 after buying an additional 297 shares during the last quarter. 11.54% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on NVO. Barclays restated an "equal weight" rating on shares of Novo Nordisk A/S in a report on Wednesday, July 30th. HSBC cut shares of Novo Nordisk A/S from a "buy" rating to a "hold" rating and set a $57.00 price target for the company. in a research note on Thursday, July 31st. TD Cowen dropped their price target on shares of Novo Nordisk A/S from $105.00 to $70.00 and set a "buy" rating for the company in a research note on Tuesday, August 19th. Hsbc Global Res cut shares of Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a research note on Thursday, July 31st. Finally, Zacks Research cut shares of Novo Nordisk A/S from a "hold" rating to a "strong sell" rating in a research note on Wednesday, August 20th. Three analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus target price of $81.00.

Novo Nordisk A/S Trading Up 0.7%

Novo Nordisk A/S stock traded up $0.37 during trading hours on Wednesday, hitting $56.75. The company had a trading volume of 9,034,647 shares, compared to its average volume of 11,742,110. The firm has a market cap of $253.41 billion, a P/E ratio of 15.59, a P/E/G ratio of 1.96 and a beta of 0.66. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.56 and a current ratio of 0.78. Novo Nordisk A/S has a 1 year low of $45.05 and a 1 year high of $138.22. The company has a 50-day moving average price of $60.17 and a two-hundred day moving average price of $68.04.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last released its quarterly earnings data on Wednesday, August 6th. The company reported $0.97 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.93 by $0.04. The company had revenue of $11.69 billion during the quarter, compared to analysts' expectations of $77.51 billion. Novo Nordisk A/S had a net margin of 35.60% and a return on equity of 78.64%. On average, sell-side analysts anticipate that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Cuts Dividend

The business also recently disclosed a semi-annual dividend, which was paid on Tuesday, August 26th. Shareholders of record on Monday, August 18th were given a $0.4119 dividend. This represents a yield of 240.0%. The ex-dividend date of this dividend was Monday, August 18th. Novo Nordisk A/S's payout ratio is 22.53%.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.